SEC Form 4 · accession 0001246360-15-001833
SYNAGEVA BIOPHARMA CORP · GEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony Quinn
Officer — EVP, CMO & Head of R&D
Period of report
Apr 21, 2015
Accepted (ET)
Apr 23, 2015 · 7:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000911326
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 21, 2015 | S | 10,000 | $108.00 | D | 5,637 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale of shares of the Company's common stock (the "Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 6, 2015.